🇺🇸 FDA
Patent

US 9212149

Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors

granted A61PA61P19/02A61P29/00

Quick answer

US patent 9212149 (Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors) held by Takeda Pharmaceutical Company Limited expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Dec 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61P, A61P19/02, A61P29/00, A61P43/00